Compagnie Lombard Odier SCmA’s Myriad Genetics MYGN Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-500	Closed	-$6K	–	559
2020 Q2	$6K	Hold	500	–	–	﹤0.01%	494
2020 Q1	$7K	Hold	500	–	–	﹤0.01%	451
2019 Q4	$14K	Hold	500	–	–	﹤0.01%	433
2019 Q3	$14K	Hold	500	–	–	﹤0.01%	436
2019 Q2	$14K	Hold	500	–	–	﹤0.01%	440
2019 Q1	$17K	Buy	+500	New	+$15.2K	﹤0.01%	472
2016 Q2	–	Sell	-100	Closed	-$4K	–	949
2016 Q1	$4K	Buy	+100	New	+$3.77K	﹤0.01%	933
2015 Q4	–	Sell	-4,000	Closed	-$150K	–	956
2015 Q3	$150K	Hold	4,000	–	–	0.01%	456
2015 Q2	$136K	Hold	4,000	–	–	0.01%	502
2015 Q1	$142K	Buy	4,000 +1,000	+33%	+$35.8K	0.01%	571
2014 Q4	$102K	Buy	3,000 +1,000	+50%	+$35.5K	﹤0.01%	546
2014 Q3	$77K	Hold	2,000	–	–	﹤0.01%	678
2014 Q2	$78K	Hold	2,000	–	–	﹤0.01%	698
2014 Q1	$68K	Buy	2,000 +940	+89%	+$29.1K	﹤0.01%	693
2013 Q4	$22K	Buy	+1,060	New	+$26.8K	﹤0.01%	774

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Compagnie Lombard Odier SCmA's MYGN Position: Q3 2020 in Review

Compagnie Lombard Odier SCmA sold out of Myriad Genetics (MYGN) in Q3 2020, closing a stake of 500 shares — an estimated $6K sold.

Compagnie Lombard Odier SCmA first reported a position in MYGN in Q4 2013 and held it in 15 quarters. The position peaked at $150K in Q3 2015. 192 funds tracked by Wall St. Rank hold MYGN as of Q3 2020.

Compagnie Lombard Odier SCmA reported no remaining Myriad Genetics position as of Q3 2020 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 500 Myriad Genetics shares in Q3 2020, an estimated $6K.
Compagnie Lombard Odier SCmA first reported a position in Myriad Genetics in Q4 2013 and held it in 15 quarters.
Compagnie Lombard Odier SCmA's Myriad Genetics position peaked at $150K in Q3 2015.
192 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2020.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2020, filed 12 Nov 2020.